Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
  • Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study
  • Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced yet familiar experience for patients
  • Submission builds on Sandoz’ well established biosimilar immunology portfolio in Europe

Basel, June 17, 2022 — Sandoz, a global leader in generic and biosimilar medicines, today announced that the European Medicines Agency (EMA) has accepted the application for high concentration  …

/by